Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 1, First-in-human Study of VX-433
Sponsor: Vertex Pharmaceuticals Incorporated
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VX-433 following single and multiple ascending doses, as well as to assess the effect of VX-433 on the PK of midazolam, bupropion, and hydroxybupropion.
Official title: A Phase 1, First-in-human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VX-433 and Its Effects on the Pharmacokinetics of Midazolam and Bupropion
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
118
Start Date
2026-05-12
Completion Date
2027-03-05
Last Updated
2026-05-13
Healthy Volunteers
Yes
Conditions
Interventions
VX-433
Suspension for Oral Administration
Placebo
Suspension for Oral Administration
Midazolam
Syrup for Oral Administration
Bupropion
Capsule for Oral Administration